The effect of MDR1 (C3435T) and NR1I2 (C25385T) polymorphisms on tacrolimus dose requirements in kidney transplant patients

Abstract

Renal transplantation is utilized for treatment of patients with end-stage renal disease renal disease. It should be used immunosuppressive drugs such as tacrolimus for prevention of allograft rejection and it seems that MDR1 and NR1I2 genes are responsible for partially regulation of its absorption and metabolism. Therefore, the aim of this study was evaluation of relationship between C3435T MDR1 and C25385T NR1I2 polymorphisms with blood concentration of tacrolimus in transplanted patients. Material & methods Blood samples of 70 patients were collected after renal transplantation surgery for DNA extraction. Then, DNA samples were amplified with PCR manner and via specified primers. Finally, data analysis were performed by SPSS software. Results Our study’s results demonstrated that presence of neither C3435T MDR1 nor C25385T NR1I2 polymorphisms were significantly affected blood concentration of tacrolimus in second (P= 0.285, 0.246), fourth (P= 0.634, 0.221), and eighth (P= 0.772, 0.536) week after starting treatment in transplanted patients.